Nature Medicine reports on the development of a new oral GLP-1 drug designed to treat obesity. Unlike current peptide-based treatments that require subcutaneous injection, this non-peptide version is administered as a pill, offering easier storage and usage. The advancement aims to improve accessibility and adherence for patients requiring weight management therapies.